We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Financial disclosures
- Endometrial cancer 2025
- Moving from the light microscope to the molecular microscope
- Traditional classification of endometrial cancer: Type I vs. Type II
- Endometrial cancer molecular classification
- ProMisE: Molecular risk stratification in endometrial cancer
- Immunotherapy and ADCs based on molecular characterization
- Single agent IO in “biomarker” selected endometrial cancer populations (dMMR)
- Single agent IO in “non-biomarker” selected endometrial cancer populations
- Study 309/KEYNOTE-775
- First-line treatment of advanced or recurrent endometrial cancer
- GOG-209
- Incorporation of anti-HER-2 treatment: Trastuzumab with chemotherapy
- First-line IO + chemotherapy in advanced or recurrent endometrial cancer
- Pivotal phase III trials of immunotherapy in advanced endometrial cancer
- NRG GY018: Progression-free survival
- NRG GY018: Overall survival
- GOG-3031/RUBY
- GOG-3031/RUBY: PFS according to molecular subgroup
- GOG-3031/RUBY: Longer follow-up _x000B_of OS (IA2)
- DUO-E study design
- DUO-E: Maintenance durvalumab ± olaparib on PFS in ITT population
- DUO-E: Subgroup analysis of PFS by MMR status
- Adding PARP inhibition to first line
- TP53-mutated pMMR subpopulation: Impact of adding olaparib
- RUBY part 2
- RUBY part 2: Identifying subgroups that may benefit from adding PARPi
- AtTEnd: dMMR EC cohort PFS and OS
- Benefits of IO + chemotheraphy in the dMMR EC population
- Recent FDA aprovals in dMMR EC: A paradigm shift
- Benefit of IO + chemotherapy in the pMMR EC population
- FDA approvals and variability in pMMR study outcomes
- De-escalating therapy in dMMR EC: Can we learn from Keynote-177?
- Ongoing trials exploring first-line chemotherapy-free options in EC
- ENGOT-en9/LEAP-001 (1)
- ENGOT-en9/LEAP-001 (2)
- Adjuvant therapy
- GOG-3031/RUBY: PFS Subgroups
- GOG-3031/RUBY: OS subgroups
- What about IO in early stage completely resected EC?
- ENGOT-EN11/GOG-3053/KEYNOTE-B21: ITT
- ENGOT-EN11/GOG-3053/KEYNOTE-B21: dMMR
- Disease specific survival with pembrolizumab in pMMR and dMMR EC
- Disease free survival by specific factors of interest in the dMMR subgroup
- Adjuvant therapy: High risk
- Evolution of molecularly directed therapy in endometrial cancer
- Selinexor is a targeted oral XPO1 inhibitor
- ENGOT-EN5/GOG-3055/SIENDO: PFS in ITT and TP53 WT population
- XPORT-EC-042
- Mechanism of antibody drug conjugate
- ADCs in the endometrial cancer space
- DESTINY-PanTumor02
- DESTINY-Endometrial01/ GOG-3098/ENGOT-EN24
- Preliminary efficacy of ADCs in EC
- Rinatabart sesutecan anti-tumor activity
- TroFuse-005: Phase 3 ENGOT-en23/GOG-3095/MK-2870-005
- GOG-3119/ENGOT-en29/TroFuse-033
- ASCENT-GYN-01/GOG-3104/ENGOT-en26
- WEE1 inhibitor: Active in p53-mutant background
- WEE-1 inhibitors in EC
- GOG-3065/ZN-c3-004/TETON
- INCB123667: Selective CDK2 inhibitor
- Results of INCB123667: Antitumor activity
- INCB123667: Results and conclusions
- E7386 Study 102
- E7386: Inhibits interaction between β-catenin and CREB-binding protein
- ACR-368: A clinically active phase 2 CHK1/2 inhibitor
- ACR-368 oncosignature test
- ACR-368 oncosignature response
- ACR-368 oncosignature response: ORR vs. BOR
- Hormonal therapy: ER is prognostic factor
- ER is prognostic factor in NSMP group
- Hormonal therapy in EC
- Biomarker-based therapies in EC
- Fulvestrant + abemaciclib in HR+ advanced or recurrent EC
- GOG-3069
- GOG-3111
- MK-5684: Mechanism of action
- Study design
- Thank you
Topics Covered
- Endometrial cancer
- Classification of endometrial cancer
- Single agent immunotherapy in biomarker selected endometrial cancers
- First-line treatment of advanced or recurrent endometrial cancer
- Adding PARP inhibition to first line
- Adjuvant therapy
- Antibody drug conjugates in endometrial cancer
- Cell cycle checkpoint inhibitors in endometrial cancers
- Hormonal therapy
- Biomarker based therapy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Slomovitz, B. (2026, July 30). Current & emerging therapies for the management of patients with endometrial cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 5, 2026, from https://doi.org/10.69645/XDLA7841.Export Citation (RIS)
Publication History
- Published on July 30, 2026
Financial Disclosures
- Brian Slomovitz is a Consultant or Advisory Board member for AstraZeneca, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, GSK, ImmunoGen Inc, Novocure GmbH, Onconova Therapeutics, Seagen, AbbVie and Pfizer.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Good day. My name is
Dr. Brian Slomovitz.
I'm the Director of
Gynecologic Oncology at
Mount Sinai Medical Center
in Miami Beach, Florida,
and I also serve
as a Professor of
Obstetrics and Gynecology
at the Florida
International University.
I'm also a member
of the board of
directors of the GOG Foundation,
and I am the clinical
trial lead for
the GOG Partners in
endometrial cancer.
Today, I'll be discussing
current and emerging
therapies for
the management of patients
with endometrial cancer.
0:32
Here are my disclosures.
0:35
Endometrial cancer is the
only gynecologic cancer
with a rising incidence
and mortality.
Amazingly, the number
of deaths due to
endometrial cancer now exceeds
the number of deaths
due to ovarian cancer,
which had traditionally been
known as the silent killer.
When we look at
endometrial cancer,
we consider that
two-thirds of them
are what I like to
call won and done.
We get a biopsy.
We identify a cancer,
and these patients are
treated with a hysterectomy,
require no further therapy,
and go on and live a
long, healthy life
without worrying
about their disease.
It's the one-third of the
cases who have advanced or
recurrent disease
that account for
the high rising death rate
due to endometrial cancer.
This represents the unmet need
to where we need to get
better treatment options.
1:25
One thing that's nice about
endometrial cancer over
the last decade is that
we've really changed from
looking at light microscopy to
more molecular
microscopic makeup
of tumor classification.
As I go forward, I'll
describe further.